March 11, 2020 / 11:28 AM / a month ago

BRIEF-Redhill Biopharma Provides Update On Opaganib

March 11 (Reuters) -

* REDHILL BIOPHARMA PROVIDES UPDATE ON OPAGANIB (YELIVA®)

* REDHILL BIOPHARMA LTD - PURSUING AN EXPLORATORY PROGRAM OF OPAGANIB AND RHB-107 INDIVIDUALLY AND IN COMBINATION WITH HYDROXYCHLOROQUINE AND OTHER COMPOUNDS FOR TREATMENT OF COVID-19

* REDHILL BIOPHARMA LTD - INVESTIGATOR-SPONSORED PHASE 2 STUDY EVALUATING OPAGANIB IN PROSTATE CANCER HAS BEEN INITIATED AT MEDICAL UNIVERSITY OF SOUTH CAROLINA

* REDHILL BIOPHARMA LTD - HAS ADDED A SECOND ARM TO STUDY, EVALUATING OPAGANIB IN COMBINATION WITH HYDROXYCHLOROQUINE

* REDHILL BIOPHARMA LTD - RECRUITMENT FOR SECOND ARM OF PHASE 1/2A STUDY HAS BEEN INITIATED

* REDHILL BIOPHARMA LTD - PLANS TO ADD A THIRD ARM TO STUDY, EVALUATING OPAGANIB IN COMBINATION WITH RHB-107 (UPAMOSTAT) Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below